inhibitor hypoglycemic agent empagliflozin (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol 2025-07-18T10:46:51Z CHEBI:82720 GEO:GSE263155 Jardiance MESH:C570240 PMID:40409667 This is any condition in which the main influencing factor is empagliflozin, an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporter primarily responsible for the reabsorption of glucose in the kidney. It is used as a hypoglycemic agent for the management of type 2 diabetes mellitus. XCO:0001684 experimental_condition_ontology slaulederkind